Adrian Towse - OHE

Office of Health Economics

Leading intellectual authority on global health economics

Search publications, topics, authors and more

Newsletter SignupSubscribe

News & Insights

News
Events
Insights
Bulletin

News
Events
Insights
Bulletin

News & Insights

News
Events
Insights
Bulletin

Newsletter SignupSubscribe

News
Events
Insights
Bulletin

Search publications, topics, authors and more

Research & Publications
News & Insights
Education
Innovation Policy Prize

Events
About Us
OHE Experts
Join OHE
Contact Us

Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:

Antimicrobial Resistance (AMR)
Biosimilars
Cell and Gene Therapies
Chronic Diseases
Combination Therapies
COVID-19 Research
Digital Health
Drug Development/R&D
Emerging Markets
EQ-5D and PROMs
Indication-Based Pricing
Health Care Systems
Health Data and Statistics
Health Technology Assessment
Precision Medicine
Prevention
Real-World Evidence
Sustainability
Use of Medicines
Value-Based Pricing
Vaccine Research

Economics of Innovation
Measuring and Valuing Outcomes
Policy, Organisation and Incentives in Health Systems
Value, Affordability and Decision Making

News & Insights

News
Events
Insights
Bulletin

Education

Education Hub
OHE Graduate School
EVIA Programme

Innovation Policy Prize

The Prize Fund
2024 Prize Fund
2022 Prize Fund

Search publications, topics, authors and more

Latest Research & Publications

Cell and Gene Therapies
Economics of Innovation
Innovation

Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures

Measuring and Valuing Outcomes
Clinical Outcomes

Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

Health Care Systems
Policy, Organisation and…
Health Policy and Regulation

Can a Strong Economic Case Be Made for Investing in the NHS?

Health Data and Statistics
Economics of Innovation
Innovation

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

Combination Therapies
Economics of Innovation
Health Policy and Regulation

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

Economics of Innovation

2017 OHE Annual Report to the Charity Commission

Health Care Systems
Policy, Organisation and…
Health Policy and Regulation

Securing Funds for the Proposed NHS Multi-year Funding: The Feasibility of Using a Hypothecated Tax

Health Care Systems
Policy, Organisation and…
Health Policy and Regulation

Private Provision of Publicly Funded Health Care: The Economics of Ownership

All Publications

Filter by:

Antimicrobial Resistance (AMR)

Biosimilars

Cell and Gene Therapies

Chronic Diseases

Combination Therapies

COVID-19 Research

Digital Health

Drug Development/R&D

Emerging Markets

EQ-5D and PROMs

Indication-Based Pricing

Health Care Systems

Health Data and Statistics

Health Technology Assessment

Precision Medicine

Prevention

Real-World Evidence

Sustainability

Use of Medicines

Value-Based Pricing

Vaccine Research

Economics of Innovation

Measuring and Valuing Outcomes

Policy, Organisation and Incentives in Health Systems

Value, Affordability and Decision Making
News

Events

Insights

Bulletin
Education Hub

OHE Graduate School

EVIA Programme
The Prize Fund

2024 Prize Fund

2022 Prize Fund

Events
About Us
OHE Experts
Join OHE
Contact Us

Newsletter SignupSubscribe

Filter results by

Theme

Select the product option you would like to filter Theme

Economics of Innovation Measuring and Valuing Outcomes Policy, Organisation and Incentives in Health Systems Value, Affordability, and Decision Making

Topic

Select the product option you would like to filter Topic

Antimicrobial Resistance (AMR) Biosimilars Cell and Gene Therapies Chronic Diseases Combination Therapies COVID-19 Research Dementia Digital Health Drug Development/R&D Emerging Markets EQ-5D and PROMs Health Care Systems Health Data and Statistics Health Technology Assessment (HTA) Indication-Based Pricing Innovation Policy Prize OHE Consulting Precision Medicine Prevention Real World Evidence (RWE) Research Sustainability Use of Medicines Vaccines Value-Based Pricing

Tag

Select the product option you would like to filter Tag

Adult Immunisation Alzheimer's Cancer Cardiovascular Disorders Care-givers Caring burden Cervical Cancer Clinical Outcomes Commentary Competition Dermatology Determining Value Drug Shortages Economic Evaluation Egypt Epidemiology and Public Health Epilepsy Gene therapies Generics Greece Haemophilia Health Policy and Regulation Healthcare Delivery Healthcare Expenditure Healthcare Funding Healthcare System Pressure (HCSP) India Infectious Diseases Inflation Reduction Act Injury and Trauma Innovation Israel Market Access Mental Health Pharmaceutical Industry Plant-based Policy Analysis Pricing and Reimbursement Primary Care Quality of Care Quality of Life Rare and Orphan Diseases Research Funding Resource Allocation Saudi Arabia Slovak Republic Societal preferences Supply of Medicine Türkiye Unmet Need Vaccines Value based pricing Webinar

Date 1

Select the product option you would like to filter Date

Date From

Month From

Year From

Date To

Month To

Year To

Author

Select the product option you would like to filter Author

Search authors

Andrew Briggs Thomas Pogge Antonella Cardone Stan Jackson Claudio Jommi Carole Longson Dr Tina Wang Lishani Ramanayake Sukanya Subramaniyan Brittany Darrow

Content Type

Select the product option you would like to filter Content Type

news story insight events podcast bulletin publications

2021 OHE Annual Report to the Charity Commission

Sustainability

Supporting the Era of Green Pharmaceuticals in the UK

News
January 2022

OHE Announces New Trustees and Board Chair

Bulletin
January 2022

January 2022

Drug Development/R&D
Economics of Innovation
Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

Cell and Gene Therapies
Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

Health Technology Assessment…
Measuring and Valuing Outcomes

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

News
December 2021

OHE Thanks Trustees for Their Service

Vaccine hesitancy concept, syringes with vaccine and question ma

Bulletin
December 2021

December 2021

Insight
December 2021

OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates

News
November 2021

Opportunity Cost in Health Care: a Favourite Research Topic for OHE

Tired young man in need of mental support. Reaching out for help

Bulletin
November 2021

November 2021

News
October 2021

We have launched OHE Bulletin, a new monthly newsletter

Bulletin
October 2021

October 2021

Leading intellectual authority on global health economics

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Cookies Policy

An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Twitter

Facebook

Copy

Share on Mastodon

Enter your Mastodon instance URL (optional)

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures

Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

Can a Strong Economic Case Be Made for Investing in the NHS?

Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

2017 OHE Annual Report to the Charity Commission

Securing Funds for the Proposed NHS Multi-year Funding: The Feasibility of Using a Hypothecated Tax

Private Provision of Publicly Funded Health Care: The Economics of Ownership

All Publications

Filter results by

2021 OHE Annual Report to the Charity Commission

Supporting the Era of Green Pharmaceuticals in the UK

OHE Announces New Trustees and Board Chair

January 2022

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

OHE Thanks Trustees for Their Service

December 2021

OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates

Opportunity Cost in Health Care: a Favourite Research Topic for OHE

November 2021

We have launched OHE Bulletin, a new monthly newsletter

October 2021